was downgraded to buy from strong buy at
Friday, but the firm still likes the supplemental insurance provider with those kooky
commercials we all know and love.
UBS raised the price target to $77 from $69 and noted that AFLAC enjoys great visibility and growth potential. But in lowering the rating, the brokerage expressed the opinion that the stock isn't likely to rally with the same kind of fever as it has in the last few months.
The shares recently traded down $2.38 to $65.19 in
New York Stock Exchange